Animal study suggests CBD and CBG improve liver health in adults with fatty liver — Evidence Review

Scientists at the Hebrew University of Jerusalem identified two non-intoxicating cannabis compounds, CBD and CBG, that improve liver metabolism and reduce liver fat in animal models of fatty liver disease. Related studies largely support these findings, indicating cannabinoids may benefit liver health and metabolic function.

• Multiple observational and experimental studies report associations between cannabis or its components (especially CBD and CBG) and reduced prevalence or severity of non-alcoholic fatty liver disease (NAFLD), improved insulin sensitivity, and lower markers of liver inflammation and fibrosis 1 2 6 7 10.
• Research suggests cannabinoids may act through diverse mechanisms, including modulation of lipid metabolism, suppression of inflammation, and regulation of key metabolic pathways, which aligns with the new study’s focus on energy storage and lysosomal function 2 7 10.
• Some studies highlight dose sensitivity and possible risks at higher cannabinoid doses, underscoring the importance of further investigation into optimal therapeutic windows and safety profiles 6 8.

Study Overview and Key Findings

Metabolic dysfunction-associated steatotic liver disease (MASLD), also known as non-alcoholic fatty liver disease (NAFLD), affects nearly one-third of adults worldwide and is closely linked to obesity and metabolic syndrome. Current treatment options are limited, with most therapies relying on lifestyle modifications that can be difficult to sustain. The study from the Hebrew University of Jerusalem explores whether two non-intoxicating cannabis-derived compounds, cannabidiol (CBD) and cannabigerol (CBG), can offer a new, plant-based approach to improving liver health and metabolic function.

The research goes beyond simple fat reduction, examining how CBD and CBG affect liver energy management and cellular waste disposal. By enhancing the liver’s backup energy capacity and restoring lysosomal cathepsin activity, the compounds show potential to address multiple aspects of metabolic dysfunction in fatty liver disease, at least in animal models.

Property	Value
Organization	School of Pharmacy at the Faculty of Medicine of the Hebrew University of Jerusalem
Authors	Prof. Joseph (Yossi) Tam, Dr. Liad Hinden, Radka Kočvarová
Population	Adults with fatty liver disease
Methods	Animal Study
Outcome	Liver fat reduction, metabolic health improvement
Results	CBD and CBG improved liver health and metabolic markers.

Literature Review: Related Studies

To assess how the new findings fit with existing research, we searched the Consensus database, which indexes over 200 million scientific papers. The following search queries were used:

1. cannabis compounds fatty liver disease
2. CBD CBG liver health metabolic markers
3. therapeutic effects cannabinoids liver function

Summary Table of Key Topics and Findings

Topic	Key Findings
Do cannabinoids reduce fatty liver disease risk or severity?	- Cannabis use is linked to lower prevalence of NAFLD/steatosis in large observational and clinical studies 1 5. - CBD, CBG, and other cannabinoids reduce liver fat, improve liver function, and decrease inflammation and fibrosis in animal models 2 3 6 7 10 14.
What mechanisms underlie cannabinoid effects on liver health?	- Cannabinoids modulate lipid metabolism, inflammation, and insulin sensitivity through CB1/CB2 receptors and other pathways 2 4 6 7 10 12 13. - Both CBD and CBG impact hepatic glucose and lipid processing, sphingolipid metabolism, and lysosomal function 7 9 10.
Are the metabolic benefits of CBD and CBG observed in other models?	- Chronic CBD or CBG administration in rodents leads to improved insulin sensitivity, lower triglycerides, and altered metabolic markers 6 7 8 9. - Cannabinoids may also attenuate alcohol-induced and diet-induced liver injury and steatosis 2 3 10.
What are the safety considerations and possible risks of cannabinoid use?	- Dose-dependent effects are reported: low-dose CBG is beneficial, while high-dose CBG may worsen liver damage in animal models 6. - Long-term or high-dose cannabinoid administration can alter metabolic activity in complex ways, highlighting the need for careful dosing and monitoring 8.

---

Do cannabinoids reduce fatty liver disease risk or severity?

A substantial body of research suggests that cannabinoids—whether from whole cannabis, CBD, CBG, or other derivatives—are associated with reduced risk or severity of fatty liver disease in both human and animal models. The new study’s findings that CBD and CBG improve liver fat and metabolic markers in fatty liver disease are consistent with these broader observations.

• Observational studies in large human cohorts have found lower rates of NAFLD among cannabis users, even after adjusting for confounders 1 5.
• Animal studies using both CBD and CBG demonstrate reductions in liver fat, fibrosis, and inflammation, mirroring effects reported in the new research 2 6 7 10 14.
• Cannabinoids have been shown to reduce diet- and alcohol-induced liver steatosis and injury in preclinical models 2 3 10.
• The protective effect may be partly related to cannabinoid modulation of weight gain and metabolic syndrome components 5.

What mechanisms underlie cannabinoid effects on liver health?

Cannabinoids exert their effects through a variety of mechanisms. The new study’s focus on metabolic remodeling and lysosomal function aligns with evidence that these compounds influence lipid metabolism, inflammation, and insulin signaling via the endocannabinoid system and other pathways.

• CB1 and CB2 receptor signaling influences hepatic lipid synthesis, fatty acid oxidation, and inflammation 4 12 13.
• CBD and CBG have been found to regulate key metabolic enzymes, suppress inflammatory pathways such as the NLRP3 inflammasome, and alter sphingolipid metabolism in the liver 2 7 9 10.
• The restoration of lysosomal cathepsin activity and backup energy stores, as observed in the new study, may represent novel mechanisms contributing to improved hepatic function 7 10.
• These pathways potentially complement traditional targets in metabolic disease treatment, offering new avenues for therapeutic intervention.

Are the metabolic benefits of CBD and CBG observed in other models?

The beneficial effects of CBD and CBG on metabolic health, observed in the animal model of the new study, are echoed in a range of rodent studies exploring diverse metabolic endpoints.

• Repeated CBD or CBG administration leads to improved insulin sensitivity, lower liver triglycerides, and favorable changes in blood lipid profiles in animal models of obesity, diabetes, and insulin resistance 6 7 8 9.
• These cannabinoids also affect glucose metabolism—sometimes as strongly as standard antidiabetic drugs in preclinical testing 9.
• Protective effects extend to alcohol-induced and high-fat diet-induced liver disorders, with reductions in liver steatosis and inflammation 2 10.
• However, some metabolic alterations depend on timing and dosing, with potential for paradoxical effects (e.g., increased hypothalamic triglycerides after juvenile CBD exposure) 8.

What are the safety considerations and possible risks of cannabinoid use?

While the literature generally supports beneficial effects of CBD and CBG at appropriate doses, several studies caution that dose-dependent and long-term effects must be carefully considered.

• Low-dose CBG reduced inflammation and fibrosis, but high-dose CBG aggravated liver injury in a mouse NASH model 6.
• Long-term administration of cannabinoids during development may disrupt metabolic markers well into adulthood 8.
• The therapeutic window, optimal dosing, and safety profile for human use remain unclear and require further research before clinical recommendations can be made 6 8.
• These findings underscore the need for controlled trials to establish efficacy and safety parameters for cannabinoid-based therapies in liver and metabolic diseases.

Future Research Questions

Despite promising preclinical results, several gaps remain in translating these findings into clinical practice. Key areas for further investigation include mechanisms of action, optimal dosing, long-term safety, and efficacy in humans with fatty liver disease and related metabolic disorders.

Research Question	Relevance
What are the effects of CBD and CBG on liver fat and metabolic health in human patients with NAFLD?	Most available data are from animal models or observational studies; rigorous clinical trials are needed to confirm efficacy and safety in human populations 1 2 6.
How do different doses of CBD and CBG affect liver function, fibrosis, and inflammation?	Dose-dependent effects, including potential harm at high doses, have been reported in animal studies, emphasizing the importance of defining safe and effective therapeutic windows 6 8.
What cellular and molecular mechanisms mediate the metabolic remodeling effects of CBD and CBG in the liver?	Understanding how cannabinoids enhance energy storage and lysosomal function may identify new therapeutic targets and clarify potential side effects 7 9 10.
Are the metabolic benefits of CBD and CBG sustained with long-term use or do they vary with age and health status?	Long-term safety and efficacy, especially across different populations and health conditions, are not well established and require further longitudinal research 5 8.
Can CBD and CBG be combined with existing liver disease therapies for additive or synergistic effects?	Exploring combination therapies could enhance treatment efficacy for MASLD/NAFLD, especially given the limited options currently available 2 13.